Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q13405

UPID:
RM49_HUMAN

ALTERNATIVE NAMES:
39S ribosomal protein L49, mitochondrial; Neighbor of FAU; Protein NOF1

ALTERNATIVE UPACC:
Q13405; B2R4G6

BACKGROUND:
Large ribosomal subunit protein mL49, identified by alternative names such as 39S ribosomal protein L49, mitochondrial, Neighbor of FAU, and Protein NOF1, is integral to mitochondrial protein synthesis. This protein is a component of the mitochondrial ribosome, where it supports the synthesis of proteins necessary for mitochondrial and cellular energy mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Large ribosomal subunit protein mL49 offers a promising pathway to novel therapeutic approaches. Given its essential role in mitochondrial protein synthesis, targeting this protein could provide new avenues for addressing mitochondrial-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.